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PURPOSE. The present study was designed to investigate the role of ocular surface glycocalyx
and mucins in graft versus host disease (GVHD)-associated dry eye. The ameliorative effect of
topical rebamipide, a mucin secretagogue, on GVHD-associated dry eye was also tested.
METHODS. A mouse model of allogeneic transplantation was used to induce ocular GVHD with
C57BL/6 as donors and B6D2F1 as recipient mice. Phenol red thread method and fluorescein
staining was used to quantify tear secretion and corneal keratopathy. At 8 weeks after the
allogeneic transplantation, corneas were harvested to perform glycocalyx staining and
confocal microscopy. Goblet cell staining was performed using periodic acid Schiff’s staining.
Corneal and tear film levels of Mucin 1, 4, 16, 19, and 5AC were quantified using ELISA and
real-time PCR. Rebamipide was applied topically twice daily to mice eyes.
RESULTS. Allogeneic transplantation resulted in ocular GVHD-associated dry eye characterized
by a significant decrease in tear film volume and the onset of corneal keratopathy. Ocular
GVHD caused a significant decrease in the area and thickness of corneal glycocalyx. A
significant decrease in the goblet cells was also noted. A significant decrease in mucin 4 and
5AC levels was also observed. Topical treatment with rebamipide partially attenuated ocular
GVHD-mediated decrease in tear film volume and significantly reduced the severity of corneal
keratopathy.
CONCLUSIONS. Ocular GVHD has detrimental impact on ocular surface glycocalyx and mucins.
Rebamipide, a mucin secretagogue, partially prevents ocular GVHD-associated decrease in
tear film and reduces the severity of corneal keratopathy.
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Allogeneic hematopoietic stem cell transplantation is asuccessful treatment option for hematologic malignancies.
However, graft versus host disease (GVHD) is a serious
complication of hematopoietic stem cell transplantation and
its incidence remains high in spite of the advances in human
leukocytes antigens (HLA) matching. Depending upon the time
of onset and clinical manifestations, GVHD is divided into acute
and chronic phases. Acute GVHD primarily affects liver, skin,
and intestine.1–3 On the other hand, chronic GVHD has been
shown to cause a high incidence of ocular complications.4,5 As
high as 60% to 90% of chronic GVHD patients suffer from
ocular manifestations.4,5 Ocular signs in chronic GVHD patients
may be noticeable even before the other systemic symptoms.6–8
Dry eye disease is one of the most frequent complications of
ocular GVHD.9,10 The dry eye disease in ocular GVHD patients
is severe, resulting in symptoms of blurred vision, photophobia,
redness, gritty sensation, and pain.9,10 These symptoms cause
significant visual discomfort, and reduce the overall quality of
life of GVHD patients.9,10 In absence of timely and appropriate
treatment, dry eye disease in GVHD patients may progress to
corneal keratopathy, ulceration, and visual impairment.8,11
The lacrimal functional unit, including ocular surface
nerves, apical surface glycocalyx, lacrimal glands, meibomian
glands, and a normal blinking response, all collectively
contribute to the secretion and maintenance of a healthy tear
film.12 Tear film is critical for keeping the ocular surface
hydrated and lubricated, thus preventing desiccation-induced
damage to the ocular surface. Tear film comprises the
mucoaqueous gel layer, which underlies but partially integrates
into lipid layer.13
Mucins are high molecular weight glycoproteins made up of
a protein core with extensive glycan N-acetyl galactosamine
side chains. The heavy glycosylation imparts the mucins with
hydrophilicity and a negative charge.14–18 These structural
features account for the two key physiologic functions of ocular
surface mucins, which include repelling pathogens and
keeping the ocular surface hydrated.14–18 The mucins present
on the ocular surface and in the tear film include membrane-
bound mucins MUC1, MUC4, MUC16, and gel-forming secreted
mucins, MUC19 and MUC5AC, respectively.14–18 The mem-
brane-bound mucins are expressed on the apical surface of
corneal and conjunctival epithelial cells. The gel-forming mucin
MUC5AC in the tear film is primarily secreted by the goblet
cells.19 Lacrimal gland acinar cells have been shown to express
MUC7 transcript but the glycoprotein has not been detected in
the tear film.20 Tear film mucins keep the eye surface lubricated
and entrap allergens and pathogens.14–18 Patients with dry eye
disease show reduced levels of mucins or an alteration in the
degree of their glycosylation.21–23 A significant aqueous deficit
has been observed in the tears of GVHD patients suffering from
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dry eye.24 Multiple studies have shown that GVHD causes
lacrimal gland fibrosis.25–28 The effect of GVHD on ocular
surface mucins has not been investigated. Therefore, the aim of
the present study was to investigate the role of ocular surface
mucins in GVHD-associated dry eye and to test the ameliorative
effect of rebamipide, a mucin secretagogue, on GVHD-
associated dry eye.
METHODS
Allogeneic Bone Marrow Transplantation
The animal protocol was approved by Institutional Animal Care
and Use Committee of Chapman University. All the animal
experiments were conducted in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. A previously published mouse model of major
histocompatibility (MHC) class I mismatch-induced ocular
GVHD was used.28 The B6D2F1 mice (The Jackson Laborato-
ries, Bar Harbor, ME, USA) having a heterozygous MHC
haplotype b/d were used as recipients and C57BL/6 mice
(The Jackson Laboratories) having a homozygous haplotype b/
b were used as donors. The bone marrow and spleen cells
were harvested from 8-week-old donor female C57B6 mice.
Ten-week-old female B6D2F1 recipient mice were exposed to a
total body irradiation of 1100 cGy delivered in two equally
divided doses 3 hours apart (RS 2000 X-ray Biological
Irradiator; Rad Source Technologies, Buford, GA, USA). The
irradiated B6D2F1 mice were then injected with 23106 spleen
cells and 53106 bone marrow cells obtained from C57B6 mice
by retro-orbital injection. The mice were housed in sterile
cages, fed with diet gel (ClearH2O, Portland, ME, USA) and
received sulfatrim (0.672 mg/mL) in their drinking water for
the first 14 days. At 8 weeks after the transplantation, animals
were euthanized by CO2 administration for the collection of
ocular tissue.
The study design included three different groups of mice.
(1) The control group (no transplant; n¼6) mice included age-
matched B6D2F1 mice, which did not receive any bone
marrow or spleen cell transplantation. (2) The ocular GVHD
group (n¼ 12) included B6D2F1mice that received allogeneic
bone marrow and spleen cell transplantation. (3) The
rebamipide-treated group (n ¼ 6) included B6D2F1mice that
received allogeneic bone marrow and spleen cell transplanta-
tion and were treated with 2 lL topical ophthalmic drops of 2%
rebamipide suspended in balanced salt solution (BSS) in left
eye two times daily. The right eye of these mice received 2 lL
topical ophthalmic drops of vehicle BSS two times daily. The
2% dose of rebamipide was selected based on the previously
published studies.29 The volume of ophthalmic application was
also selected based on the previously published studies that
use 2-lL drop administration per mouse eye.30–32
Tear Quantification
Tear secretion was quantified by phenol red thread test before
the allogeneic transplantation and at weekly intervals after the
transplantation. The phenol red impregnated thread (FCI
Ophthalmics, Pembroke, MA, USA) was placed in the lower
eyelid of mice on the temporal side for 1 minute. Upon wetting
by tears, the phenol red thread changes color from yellow to
red due to pH change. After 1 minute, the thread was removed
and the length of the red color on the thread was measured.
The length was converted to the volume by using a standard
curve plotted by measuring the length of the phenol red thread
wetted with a known volume of artificial tears.31,32 Due to the
small amount of tear film volume in the mouse eyes, the
phenol red thread test typically requires longer time to obtain
consistent values. Therefore, this study used 1-minute duration
for phenol red thread test in mice as is also reported in
previous studies.33,34
Fluorescein Staining
Mice were anesthetized by intraperitoneal injection of
ketamine (100 mg/kg) and xylazine (10 mg/kg). A 1-lL sterile
solution of 0.1% fluorescein was applied to mouse eye and
imaging was performed under a green fluorescent filter using
stereomicroscope equipped with a digital camera. The
captured corneal images were divided into four hypothetical
quadrants for scoring the keratopathy using a previously
published method.35 Each quadrant was scored as follows: no
staining ¼ 0; slightly punctate staining less than 30 spots ¼ 1;
punctate staining more than 30 spots, but not diffuse ¼ 2;
diffuse staining but no positive plaque¼ 3; positive fluorescein
plaque ¼ 4. The scores of each quadrant were added to arrive
at a final grade (total maximum possible score ¼ 16).
Quantification of Glycocalyx-Stained Area and
Thickness
The eyes were collected from euthanized animals at 8 weeks
after the allogeneic transplantation and were fixed by
immersing overnight in 4% paraformaldehyde. The corneas
were isolated and blocked in 5% BSA for 20 minutes.
Glycocalyx staining on the corneas was performed using 1.5
lg/mL solution of Alexa 488 conjugated wheat germ agglutinin
lectin (Thermo Fisher Scientific, Hanover Park, IL, USA) for 20
minutes. Wheat germ agglutinin lectin binds to the N-
acetylglucosamine and N-acetylneuraminic acid residues pre-
sent on the ocular surface glycocalyx and has been used in
multiple studies, including human patients to stain corneal
glycocalyx.36–38 The stained corneas were imaged using a
confocal microscope. A total of four images were captured
from each cornea. The quantification of glycocalyx stained area
and thickness was performed using ImageJ software (http://
imagej.nih.gov/ij/; provided in the public domain by the
National Institutes of Health, Bethesda, MD, USA) in a blinded
manner.
Goblet Cell Staining
The eyes along with eyelids were harvested from euthanized
animals at 8 weeks after the allogeneic transplantation and
processed for paraffin embedding. The 7-lM thin paraffin
sections were cut and Periodic Acid Schiff’s (PAS) staining was
performed for goblet cells using a commercially available kit
(Polysciences, Inc., Warrington, PA, USA). The stained sections
were imaged at 3100 magnification using a brightfield
microscope (Keyence corporation of America, Itasca, IL, USA).
ELISA Quantification of Mucin 1, 4, and 16
At 8 weeks after the allogeneic transplantation, animals were
euthanized by CO2 administration. The eyeballs were collected
and the corneas were separated. The corneas were homoge-
nized in RIPA buffer containing protease inhibitor (Pierce,
Thermo Fisher Scientific, Hanover Park, IL, USA). The total
protein in the corneal homogenates was quantified by BCA
method using a commercially available kit (Pierce, Thermo
Fisher Scientific). The Muc1, 4, and 16 levels were quantified in
the corneal protein lysates using commercially available ELISA
kits (LSBio, Seattle, WA, USA). The mucin levels were
normalized for the milligram of total protein in the corneal
lysates.
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ELISA Quantification of Mucin 5AC
The Muc5ac levels were quantified in the tears collected from
mice at 8 weeks after the allogeneic transplantation. For tear
collection, mice were lightly anesthetized with isoflurane. A 1
lL solution of 13 PBS containing 0.1% BSA was placed on each
eye of the mouse and then collected back by using a
Drummond microcapillary tube. The 1 lL collected from each
eye was pooled and added to 8 lL of BSS solution. The tears
were stored in 808C for quantification of Muc5ac using a
commercially available ELISA kit (LSBio, Seattle, WA, USA).
Gene Expression Quantification of Mucin 1, 4, 16,
and 19
Corneas were harvested from animals at 8 weeks after
transplantation as described above. The mRNA was extracted
from the corneas using the RNeasy Mini kit (RNeasy kit; Qiagen
Inc., Valencia, CA, USA). The mRNA was immediately reverse
transcribed to cDNA using a commercially available kit
(Superscript III First-strand synthesis; Thermo Fisher Scientific)
for complementary (c)DNA synthesis. The cDNA was used to
quantify Muc1, Muc4, Muc16, and Muc19 gene expressions
using real-time PCR. A 20-lL reaction mixture containing 2 lL
of cDNA, 2 lL of forward primer (200 nM), 2 lL of reverse
primer (200 nM), and 10 lL of 23 SYBR green super mix was
run at a universal cycle (958C for 10 minutes, 40 cycles at 958C
for 15 seconds, and 558C for 60 seconds) in a thermocycler
(Biorad CFX thermocycler; Bio-Rad Laboratories, Hercules, CA,
USA). b-actin was used as the housekeeping gene. The relative
change in gene expression was calculated using DDCt method.
Statistical Analysis
The data are presented as mean 6 SEM. The data were tested
for normal distribution using D’Agostino-Pearson omnibus
normality test. One-way ANOVA followed by Dunnett’s and
Duncan’s test was used to analyze time-dependent changes in
tear film volume for Figure 1 and corneal keratopathy score for
Figure 7B, respectively. The data presented in Figures 2 to 6 for
comparing control and allogeneic transplantation groups were
analyzed using unpaired t-test. Two-way ANOVA was used for
data analysis of tear film volume presented in Figure 7A.
RESULTS
Effect of Ocular GVHD on Tear Film Volume and
Corneal Keratopathy
The present study used MHC mismatched allogeneic transplan-
tation mouse model that has been shown to develop ocular
GVHD.28 Our results further confirm that this mouse model of
allogeneic transplant results in significant manifestations of dry
eye due to ocular GVHD as is evident from a decrease in tear
film volume and appearance of corneal keratopathy. Figure 1
shows a baseline mean 6 SEM tear film volume of 300 6 30 nL
in the mice prior to the allogeneic transplantation. After the
bone marrow and spleen cell transplantation, a statistically
significant 3-fold decrease in tear film volume was noted
starting at 3 weeks and this decrease persisted until the tested
time point of 8 weeks (P < 0.05 compared with baseline). The
observed 2-week delay in the onset of tear film decrease is
anticipated because immune-mediated damage to the lacrimal
FIGURE 1. Tear film volume in mice before (baseline) and at various
time points after allogeneic bone marrow and spleen cell transplan-
tation. A significant (*P < 0.05 compared with baseline) decrease in
tear film volume was observed at 3 weeks after allogeneic transplan-
tation and it remained significantly low for the tested duration of 8
weeks.
FIGURE 2. Representative fluorescein-stained images of mouse corneas before (A) and at 8 weeks (B) after allogeneic bone marrow and spleen cell
transplantation. Quantification of fluorescein staining (C) showed significant (*P < 0.05 compared with before transplantation) corneal keratopathy
at 8 weeks after allogeneic transplantation.
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functional unit is expected to precede prior to a decrease in tear
film volume becomes apparent.
Figure 2 shows a representative fluorescein stained image of
a mouse cornea before (Fig. 2A) and at 8 weeks after the
allogeneic bone marrow and spleen cell transplantation (Fig.
2B). As can be seen in Figure 2B, the corneas of mice that
underwent allogeneic transplant showed significant punctate
and plaque staining. The scoring of fluorescein-stained corneal
images was performed in a blinded manner using a previously
described method.24 The graph in Figure 2C shows that the
corneas of mice that received allogeneic transplantation had a
mean fluorescein staining score of 8 6 0.5 (P < 0.05 compared
with before transplantation) suggesting that ocular GVHD
caused a moderate-to-severe degree of corneal keratopathy.
Effect of Ocular GVHD on Corneal Glycocalyx and
Goblet Cells
Corneal epithelial cells express three different types of
membrane-tethered mucins on their apical surface. These
mucins together with galectin 3 form a continuous network of
glycocalyx. Wheat germ agglutinin lectin binds to the sialic
acid residues present on these mucins and has been previously
used to stain the corneal glycocalyx.38 Figure 3 shows the top
and orthogonal projection confocal images of the mouse
corneas stained for glycocalyx using Alexa 488 conjugated
wheat germ agglutinin. The top view of confocal z stack images
shows a dense and uniformly distributed glycocalyx staining in
the corneas of control mice that did not receive any
transplantation (Fig. 3A). On the other hand, corneal glycoca-
lyx was sparse and patchy in the corneas obtained from mice at
8 weeks after they received allogeneic bone marrow and
spleen cell transplantation (Fig. 3B). The glycocalyx-stained
area was quantified as a percentage of the total area using
binary image analysis of 16 images. Four images were collected
from each cornea obtained from control mice (n¼ 4) and the
mice that received allogeneic transplantation (n ¼ 4). As is
evident from binary quantification data presented in Figure 3C,
a significant decrease of 37 6 9% in glycocalyx-stained area
was observed in the mice corneas that received allogeneic
transplantation compared with the control mice without any
transplantation (P < 0.05). Figures 3D and 3E show the
orthogonal projection confocal Z stack images of glycocalyx-
stained corneas. A significant decrease in the glycocalyx
thickness was observed in the corneas obtained from mice
that received allogeneic transplantation (Fig. 3D) compared
with control corneas obtained from mice without any
transplantation (Fig. 3E). Glycocalyx thickness was also
FIGURE 3. Representative confocal Z stacks images of top (A, B) and orthogonal (D, E) view of mouse corneas stained for glycocalyx (green) using
wheat germ agglutinin. Nuclei are stained blue. Panel A and B is top view of corneas obtained from control mice that did not receive any
transplantation and mice at 8 weeks after allogeneic bone marrow and spleen cell transplantation. Quantification of percent stained area (C) shows
a significant decrease (*P < 0.05 compared with control mice that received no transplantation) in the glycocalyx in mice corneas at 8 weeks after
allogeneic transplantation. Panel D and E is orthogonal view of corneas obtained from control mice that did not receive any transplantation and
mice at 8 weeks after allogeneic transplantation. Quantification (F) shows a significant decrease (*P < 0.05 compared with control mice that
received no transplantation) in the glycocalyx thickness in mice corneas at 8 weeks after allogeneic transplantation. Area and thickness
quantifications were calculated using 16 different images each of control mice (n ¼ 4) and mice that received allogeneic transplantation (n ¼ 4).
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quantified in 16 images each obtained from corneas of control
mice (n ¼ 4) and from the corneas of mice that received
allogeneic transplantation (n ¼ 4). Figure 3F shows a mean
decrease of 33 6 6.6% in the corneal glycocalyx thickness in
the mice that received allogeneic transplantation compared
with control mice (P < 0.05).
Figure 4 shows a representative image of PAS-stained goblet
cells in the eyelids of control mice and mice that underwent
allogeneic bone marrow and spleen cell transplant. It is
apparent from the staining that allogeneic bone marrow and
spleen cell transplantation–mediated ocular GVHD caused a
notable decrease in the number of goblet cells. It can also be
noted that the morphology and mucin content of goblet cells
has also been altered by the ocular GVHD in mice that received
allogeneic bone marrow and spleen cell transplant as compared
with the control mice that did not receive any transplantation.
Effect of Ocular GVHD on Mucins
We further investigated the effect of allogeneic bone marrow
and spleen cell transplantation–associated ocular GVHD on
membrane-bound Muc1, 4, and 16 mucins using corneal
homogenates and on secreted Muc5ac in tear film. Figure 5A
shows a reduction in Muc1 levels in the corneal homogenates
obtained from mice at 8 weeks after allogeneic bone marrow
and spleen cell transplantation (1.6 6 0.7 ng/mg protein) as
compared with the levels in the control corneal homogenates
obtained from mice that did not receive any transplantation
(0.8 6 0.4 ng/mg protein) but the difference was not
statistically significant. A statistically significant (P < 0.05)
decrease in corneal homogenate levels of Muc4 (Fig. 5B) and
tear film levels of Muc5ac (Fig. 5D) was also observed in the
mice that underwent allogeneic transplant as compared with
the control mice. On the other hand, a slight increase in Muc16
was observed (Fig. 5C) in the corneal homogenates of
transplanted mice compared with control mice.
To test the effect of ocular GVHD on mucin gene expression,
mRNA levels were quantified in the corneas of control mice and
in the cornea obtained from mice at 8 weeks after the allogeneic
transplant. A statistically significant (P < 0.05) 2.13 6 0.35-fold
increase in Muc1 gene expression was observed in the corneas
obtained from mice that received allogeneic transplantation
compared with control mice that did not receive any
transplantation (Fig. 6A). A 1.25 6 0.14-fold change in Muc4
mRNA levels (Fig. 6B), a 2.44 6 0.7-fold change in Muc16
mRNA (Fig. 6C), and 0.265 6 1.7 change in Muc19 mRNA (Fig.
6D) levels was observed in the corneas obtained from mice that
received allogeneic transplantation compared with control
mice that did not receive any transplantation. However, these
changes in Muc4, 16, and 19 mRNA between control and GVHD
mice were not statistically significant.
Effect of Topical Rebamipide on Ocular GVHD-
Mediated Changes in Tear Film and Corneal
Keratopathy
Last, we tested the effect of rebamipide, a mucin secretagogue,
on ocular GVHD-mediated decrease in tear film volume and
FIGURE 4. Representative images showing PAS-stained goblet cells in the tissue sections obtained from control mice (no transplant) and mice at 8
weeks after allogeneic bone marrow and spleen cell transplantation.
FIGURE 5. ELISA quantification of mucin 1 (A), mucin 4 (B), mucin 16
(C), and mucin 5AC (D) in the corneal homogenates and tears obtained
from control mice (no transplant) and mice at 8 weeks after allogeneic
bone marrow and spleen cell transplantation. A decrease in mucin 4
(*P < 0.05) and mucin 5AC (*P < 0.05) was observed compared with
the levels in control mice that received no allogeneic transplantation.
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cornel keratopathy. As can be seen from Figure 7A, twice daily
topical ophthalmic application of rebamipide attenuated
ocular GVHD-mediated decrease in tear film volume. The
results were statistically significant (P < 0.05) at weeks 3 and 4
compared with the GVHD mice who received allogeneic
transplantation but did not receive any eye drops. The BSS was
used as a vehicle for compounding rebamipide. Therefore, we
also tested the effect of topical ophthalmic application of BSS
as vehicle but BSS application in GVHD mice had no notable
effect on the tear film volume compared with untreated (no
eye drops) control GVHD mice. Further, rebamipide applica-
tion also significantly (P < 0.05) mitigated ocular GVHD-
mediated corneal keratopathy (Fig. 7B). Rebamipide-treated
GVHD mice showed a mean corneal keratopathy score of 3 6
0.25 compared with a score of 8 6 0.5 for the untreated (no
eye drops) GVHD mice (Fig. 7B). It is interesting to note
though that keeping the ocular surface hydrated by BSS vehicle
application also partly attenuated corneal keratopathy. BSS-
treated GVHD mice showed a mean corneal keratopathy score
of 5 6 0.5 compared with a score of 8 for the untreated (no
eye drops) GVHD mice (Fig. 7B).
DISCUSSION
The apical surface of the corneal and conjunctival epithelium is
covered with glycocalyx, a thin layer of glycoproteins largely
composed of membrane-tethered mucins and galectin-3.39–41
The glycocalyx forms a boundary between the ocular surface
epithelium and the tear film. Glycocalyx serves to protect the
cells against mechanical and chemical damage. An intact
glycocalyx is also essential to reduce the friction during
blinking and to keep the ocular surface hydrated.39–41 We used
fluorescent wheat germ agglutinin labeling and whole-cornea
mount three-dimensional confocal microscopy to visualize
glycocalyx on the corneas of GVHD mice. Wheat germ
agglutinin binds to N-acetyl-d-glucosamine and sialic acid side
chains of the membrane-tethered mucins and has been used to
specifically label, visualize, and quantify glycocalyx in the
cornea and vascular endothelium.36–38 Our data demonstrate a
significant decrease in the area and thickness of ocular surface
glycocalyx in mice that received allogeneic bone marrow and
spleen cell transplantation suggesting that GVHD has a
detrimental effect on the ocular surface glycocalyx.
Membrane-tethered mucins are an integral component of
glycocalyx. Thus, we further examined the effect of GVHD on
corneal epithelial membrane-tethered mucins. Our results
demonstrate that GVHD caused a significant decrease in
protein levels of membrane-tethered Muc4 but did not cause
any notable change in protein levels of membrane-tethered
Muc1 or Muc16. Interestingly, a significant increase in Muc1
gene expression was observed in the corneas of GVHD mice,
which can possibly be a compensatory response to partially
circumvent the GVHD-mediated damage to the ocular surface
glycocalyx. The ocular surface membrane-tethered mucins are
heavily glycosylated and sialylated. These glycans, besides
mucins, constitute an important component of the ocular
surface glycocalyx. Studies have demonstrated a significant
FIGURE 7. Effect of rebamipide ophthalmic drops on allogeneic bone marrow and spleen cell transplantation-mediated decrease in tear film volume
(A) and corneal keratopathy score (B). Rebamipide attenuated allogeneic transplantation mediated decrease in tear film volume and the results were
statistically significant (*P < 0.05) at 3 and 4 weeks after the allogeneic transplantation as compared with mice that also received the allogeneic
transplantation but were either treated with BSS vehicle or did not receive any eye drops. Rebamipide treatment also significantly decreased the
corneal keratopathy score (*P < 0.05 compared with no eye drop–treated mice; sP < 0.05 compared with BSS vehicle). Animals that received BSS
vehicle alone also showed significantly (*P < 0.05) lower corneal keratopathy score compared with mice that received no eye drops.
FIGURE 6. Gene expression quantification of mucin 1 (A), mucin 4 (B),
mucin 16 (C), and mucin 19 (D) in the corneal homogenates obtained
from control mice (no transplant) and mice at 8 weeks after allogeneic
bone marrow and spleen cell transplantation. A significant increase in
mucin1 gene expression (*P < 0.05) was observed compared with the
levels in control mice that received no allogeneic transplantation.
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decrease in the glycosylation and sialylation of mucins in dry
eye disease, keratinization, and contact lens wearers.23,40,42
Lectin staining used in this study primarily binds to glycan
carbohydrate part of the glycocalyx.36–38 Because we observed
a decrease solely in Muc4 while noting a significant decrease in
the area and thickness of glycocalyx, our data raise the
possibility that the observed changes in glycocalyx could
possibly be due to a reduction in glycosylation of mucins.
Although detection of Muc16 in mouse cornea was not an
objective of this study but our results show the presence of
Muc16 in the mouse corneal lysates using ELISA and real-time
PCR. The validity of our data was further confirmed by using
mouse brain tissue as a negative control (data not shown). Our
data are in contrast to two previously published papers that did
not detect Muc16 in the mouse cornea using immunostain-
ing.43,44 Different levels of detection sensitivity of the
techniques used in our study (ELISA and real-time PCR) as
compared with immunostaining detection of Muc16 in
formaldehyde-fixed paraffin sections used in the previous
studies may explain this apparent discrepancy.43,44
Besides membrane-tethered mucins, tear film also contains
soluble mucins. Goblet cells are the primary source of large
gel-forming mucin Muc5AC, which is secreted into the tear
film.45,46 The results of the present study demonstrate that
GVHD has a detrimental effect on goblet cells because a
decrease in the number of goblet cells was observed in the
tissue sections obtained from mice suffering from GVHD due
to allogeneic transplantation. The histology observations are
further supported by the ELISA quantification data showing a
significant decrease in the tear film levels of Muc5AC in GVHD
mice. Alterations in ocular surface mucins and glycocalyx has
been previously reported in nonautoimmune dry eye and dry
eye due to Sjogren’s disease.21,23,39,40 To the best of our
knowledge, this is the first study to demonstrate that GVHD
causes a damage to the ocular surface glycocalyx and alters
ocular surface mucins.
In this study, we used an allogeneic MHC heterozygous-
mismatch hematopoietic transplant mouse model to induce
ocular GVHD. Our data demonstrate that this mouse model
develops ocular GVHD-associated dry eye as demonstrated by a
significant decrease in tear film and the corneal keratopathy.
Previous studies have shown the development of ocular GVHD
in this mouse model and support the results of the present
study.28 Using this mouse model, Hassan et al.28 have
demonstrated that GVHD has a detrimental effect on the
lacrimal gland. Studies using MHC-matched allogeneic hema-
topoietic transplant mouse have also shown lacrimal gland
damage in ocular GVHD.47–49 However, our data are the first to
demonstrate that besides the lacrimal gland, GVHD also causes
damage to the ocular surface glycocalyx.
Rebamipide, an amino acid analog of 2 (1H)-quinolinone,
has long been used for the treatment of gastric ulcers.50,51 The
ophthalmic formulation of rebamipide has recently been
launched for the treatment of dry eye in Japan.52 Rebamipide
has been shown to stimulate gastric mucosal prostaglandin
production, increase gastric mucus synthesis, and scavenge
reactive oxygen radicals.53–56 Recent studies have shown that
rebamipide increases MUC1, MUC4, and MUC16 synthesis in
stratified cultures of human corneal epithelial cells.57,58 In vivo
administration of rebamipide has been demonstrated to have
an ameliorative effect in mouse model of Sjogren’s syndrome,
superoxide dismutase knockout mice, and rabbit model of dry
eye.29,59,60 Given the beneficial effects of rebamipide on
mucous layer and dry eye, we tested the effect of topical
administration of rebamipide in GVHD-associated dry eye
mouse model. Our data demonstrate that topical rebamipide
administration provided significant protection against GVHD-
associated dry eye as indicated by the sustenance of tear film
and a notable decrease in corneal keratopathy score. Interest-
ingly, topical administration of BSS vehicle alone also had some
ameliorative effect suggesting that keeping the ocular surface
hydrated can partially rescue GVHD-associated corneal kera-
topathy.
In summary, our results demonstrate that allogeneic
transplantation-associated ocular GVHD can have significant
detrimental effects on ocular surface glycocalyx and ocular
surface mucins. Further, modulation of ocular surface mucins
by rebamipide, a mucin secretagogue, can partially prevent
ocular GVHD-associated decrease in tear film and reduce the
severity of corneal keratopathy.
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